The global oncology based molecular diagnostics market is expected to grow at a CAGR of 7.5% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing incidence of cancer and rising awareness about cancer diagnosis and treatment. The increasing number of patients with cancer, coupled with the growing demand for personalized medicine, are also driving the growth of this market.
PCR segment accounted for over 50% share in 2017 and is expected to maintain its dominance throughout the forecast period due to its high accuracy in detecting DNA sequences that are specific for a particular disease or condition. Multiplex PCR segment is expected to grow at a CAGR of 8% during the forecast period due to its ability in detecting multiple targets simultaneously which helps reduce time required for testing as well as cost per test. In situ hybridization segment accounted for over 10% share in 2017 and is expected to grow at a CAGR of 9%. Isothermal nucleic acid amplification technology (INAAT) segment accounted for less than 5% share in 2017 but it has been witnessing significant growth owing to its ability in detecting low levels of DNA sequences that are specific for a particular disease or condition which makes it an ideal choice when there are no other options available such as when there’s no tissue sample available or when there’s not enough tissue sample available.
- The global Oncology Based Molecular Diagnostics market is expected to grow at a CAGR of 7.2% during the forecast period, 2018-2025.
- Increasing prevalence of cancer and rising awareness about the benefits of molecular diagnostics are some factors driving the growth of this market.
- The increasing number of cancer cases in developing countries such as China and India is also driving the growth of this market in these regions, which are expected to be among the fastest growing markets for Oncology Based Molecular Diagnostics during the forecast period, 2018-2025.
- Rising incidence rates for cancers such as breast cancer and lung cancer are also driving this market's growth globally, with breast cancer being one of the most common types worldwide with an estimated 1 in 8 women developing it at some point in their lives while lung cancer is one of leading causes for death from malignant neoplasm worldwide with an estimated 1 million deaths per year due to it according to WHO estimates from 2016-2020; both these cancers have high incidence rates globally which will drive demand for Oncology Based Molecular Diagnostics over time as well as other types such as prostate and colorectal cancers which have high incidence rates globally too but lower than those mentioned above according to WHO estimates from 2016-2020; all these factors will drive demand for Oncology Based Molecular Diagnostics over time leading to its growth during forecast period, 2018-2025.
Industry Growth Insights published a new data on “Oncology Based Molecular Diagnostics Market”. The research report is titled “Oncology Based Molecular Diagnostics Market research by Types (PCR, Multiplex PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT)), By Applications (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Other), By Players/Companies Abbott Laboratories, Bayer Healthcare, Becton Dickinson, Cepheid, Dako, Danaher Corporation, Gen Probe(Hologic), Roche Diagnostics, Siemens Healthcare”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Based Molecular Diagnostics Market Research Report
By Type
PCR, Multiplex PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT)
By Application
Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Other
By Companies
Abbott Laboratories, Bayer Healthcare, Becton Dickinson, Cepheid, Dako, Danaher Corporation, Gen Probe(Hologic), Roche Diagnostics, Siemens Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Based Molecular Diagnostics Market Report Segments:
The global Oncology Based Molecular Diagnostics market is segmented on the basis of:
Types
PCR, Multiplex PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Bayer Healthcare
- Becton Dickinson
- Cepheid
- Dako
- Danaher Corporation
- Gen Probe(Hologic)
- Roche Diagnostics
- Siemens Healthcare
Highlights of The Oncology Based Molecular Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PCR
- Multiplex PCR
- In Situ Hybridization
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- By Application:
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Based Molecular Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncology based molecular diagnostics is a type of cancer diagnostic that uses genetic sequencing to identify the specific types of cancer. This technology can be used to diagnose cancers early when they are more likely to respond to treatment.
Some of the major companies in the oncology based molecular diagnostics market are Abbott Laboratories, Bayer Healthcare, Becton Dickinson, Cepheid, Dako, Danaher Corporation, Gen Probe(Hologic), Roche Diagnostics, Siemens Healthcare.
The oncology based molecular diagnostics market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oncology Based Molecular Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oncology Based Molecular Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oncology Based Molecular Diagnostics Market - Supply Chain
4.5. Global Oncology Based Molecular Diagnostics Market Forecast
4.5.1. Oncology Based Molecular Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oncology Based Molecular Diagnostics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oncology Based Molecular Diagnostics Market Absolute $ Opportunity
5. Global Oncology Based Molecular Diagnostics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Type
5.3.1. PCR
5.3.2. Multiplex PCR
5.3.3. In Situ Hybridization
5.3.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oncology Based Molecular Diagnostics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Application
6.3.1. Breast Cancer
6.3.2. Prostate Cancer
6.3.3. Colorectal Cancer
6.3.4. Cervical Cancer
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oncology Based Molecular Diagnostics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oncology Based Molecular Diagnostics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oncology Based Molecular Diagnostics Demand Share Forecast, 2019-2026
9. North America Oncology Based Molecular Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Application
9.4.1. Breast Cancer
9.4.2. Prostate Cancer
9.4.3. Colorectal Cancer
9.4.4. Cervical Cancer
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Type
9.7.1. PCR
9.7.2. Multiplex PCR
9.7.3. In Situ Hybridization
9.7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oncology Based Molecular Diagnostics Demand Share Forecast, 2019-2026
10. Latin America Oncology Based Molecular Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Application
10.4.1. Breast Cancer
10.4.2. Prostate Cancer
10.4.3. Colorectal Cancer
10.4.4. Cervical Cancer
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Type
10.7.1. PCR
10.7.2. Multiplex PCR
10.7.3. In Situ Hybridization
10.7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oncology Based Molecular Diagnostics Demand Share Forecast, 2019-2026
11. Europe Oncology Based Molecular Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Application
11.4.1. Breast Cancer
11.4.2. Prostate Cancer
11.4.3. Colorectal Cancer
11.4.4. Cervical Cancer
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Type
11.7.1. PCR
11.7.2. Multiplex PCR
11.7.3. In Situ Hybridization
11.7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oncology Based Molecular Diagnostics Demand Share, 2019-2026
12. Asia Pacific Oncology Based Molecular Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Application
12.4.1. Breast Cancer
12.4.2. Prostate Cancer
12.4.3. Colorectal Cancer
12.4.4. Cervical Cancer
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Type
12.7.1. PCR
12.7.2. Multiplex PCR
12.7.3. In Situ Hybridization
12.7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oncology Based Molecular Diagnostics Demand Share, 2019-2026
13. Middle East & Africa Oncology Based Molecular Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Application
13.4.1. Breast Cancer
13.4.2. Prostate Cancer
13.4.3. Colorectal Cancer
13.4.4. Cervical Cancer
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oncology Based Molecular Diagnostics Market Size and Volume Forecast by Type
13.7.1. PCR
13.7.2. Multiplex PCR
13.7.3. In Situ Hybridization
13.7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oncology Based Molecular Diagnostics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oncology Based Molecular Diagnostics Market: Market Share Analysis
14.2. Oncology Based Molecular Diagnostics Distributors and Customers
14.3. Oncology Based Molecular Diagnostics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer Healthcare
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Becton Dickinson
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Cepheid
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Dako
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Danaher Corporation
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Gen Probe(Hologic)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Roche Diagnostics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Siemens Healthcare
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
